SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Petzold, A
Right arrow Articles by Giovannoni, G
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petzold, A
Right arrow Articles by Giovannoni, G
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers

A Petzold

Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK, a.petzold{at}ion.ucl.ac.uk

M J Eikelenboom

Department of Neurology, VU Medical Center, Amsterdam, The Netherlands

G Keir

Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK

C H Polman

Department of Neurology, VU Medical Center, Amsterdam, The Netherlands

B MJ Uitdehaag

Department of Neurology, VU Medical Center, Amsterdam, The Netherlands

E J Thompson

Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK

G Giovannoni

Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK

This study investigated whether the new Global Multiple Sclerosis Severity Scale (MSSS) correlated with cerebrospinal fluid biomarkers for axonal and glial pathology. The MSSS correlated with the phosphorylated neurofilament heavy chain (NfH-SMI35, R=0.44, P=0.016). The degree of neurofilament phosphorylation (ratio NfH-SMI34 to NfH-SMI35) was 8-fold higher in severely (median MSSS 6.5) versus mildly (MSSS 3.2) disabled patients (7.3 versus 0.9, P=0.03). The MSSS may provide a statistically powerful tool for comparing overall disease severity and be useful for validating the biomarker concept in MS.

Key Words: biomarker • MSSS • multiple sclerosis

Multiple Sclerosis, Vol. 12, No. 3, 325-328 (2006)
DOI: 10.1191/135248505ms1277oa
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
C. E. Teunissen, E. Iacobaeus, M. Khademi, L. Brundin, N. Norgren, M.J.A. Koel-Simmelink, M. Schepens, F. Bouwman, H. A.M. Twaalfhoven, H. J. Blom, et al.
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis
Neurology, April 14, 2009; 72(15): 1322 - 1329.
[Abstract] [Full Text] [PDF]


Advertisement